WO2001002554A2 - Procede de selection a haut rendement de molecules en interaction - Google Patents

Procede de selection a haut rendement de molecules en interaction Download PDF

Info

Publication number
WO2001002554A2
WO2001002554A2 PCT/EP2000/006271 EP0006271W WO0102554A2 WO 2001002554 A2 WO2001002554 A2 WO 2001002554A2 EP 0006271 W EP0006271 W EP 0006271W WO 0102554 A2 WO0102554 A2 WO 0102554A2
Authority
WO
WIPO (PCT)
Prior art keywords
tag
molecule
molecules
protein
phage
Prior art date
Application number
PCT/EP2000/006271
Other languages
English (en)
Other versions
WO2001002554A3 (fr
Inventor
Gerald Walter
Zoltán KONTHUR
Hans Lehrach
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority to EP00949254A priority Critical patent/EP1198566A2/fr
Priority to CA002378573A priority patent/CA2378573A1/fr
Publication of WO2001002554A2 publication Critical patent/WO2001002554A2/fr
Publication of WO2001002554A3 publication Critical patent/WO2001002554A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles

Definitions

  • the present invention relates to a method for the selection of at least one member of a number of specifically interacting molecules, said method being carried out in (a) container(s), preferably representing an arrayed form, e.g. in (a) microtiter plate(s), using an automated device comprising a magnetic particle processor.
  • the present invention relates to a method for the production of a pharmaceutical composition comprising the steps of the method of the present invention and further the step of formulating at least one of said specifically interacting molecules selected and/or characterized by the above method or a functionally and/or structurally equivalent derivative thereof in a pharmaceutically acceptable form.
  • yeast Two-Hybrid-System Mendelsohn & Brent, Science 284, 1999, 1948-1950
  • phage display e.g. phage display.
  • the yeast Two-Hybrid- System has the following disadvantages: (i) transformation efficiency in yeast is low; (ii) protein interactions take place in the milieu of the yeast nucleus and, therefore, interaction parameters can not be controlled; and (iii) only protein-protein interactions are possible to be investigated.
  • In vitro (e.g. phage surface) display enables the construction of large recombinant peptide and protein libraries for the selection of interacting molecules.
  • the basic concept is a physical link of the phenotype, expressed as gene product (e.g. displayed on the phage surface) to its coding genetic information (e.g. integrated into the phage genome).
  • This allows to survey large libraries of organisms (e.g. phage, viruses, bacteria, eukaryotic cells) and/or organelles (e.g. ribosome) and/or soluble molecules (e.g. nucleic acids, protein-nucleic acid hybrids) for the presence of specific molecules using the discriminative power of affinity purification.
  • the selection procedure involves the enrichment of a specific first molecule by binding to an immobilized second (target) molecule.
  • First molecules are enriched by selection (binding and elution) on the target molecule.
  • sequencing the DNA of the encoding first molecule can readily elucidate the amino acid sequence of the selected gene product.
  • Peptide libraries were the first libraries to be displayed on phage (Smith, 1985). In the meantime, a wide variety of different peptide libraries were made, with different degrees of randomness and special means of recombination (e.g., Fisch et al., 1996). Peptide libraries are especially useful for mapping interacting parts of proteins (e.g., domains or epitopes). They are also a first step towards the production of small molecules simulating protein actions.
  • Recombinant immunoglobulin gene libraries cloned in phage or phagemid vectors are an in vitro simulation of antibody repertoires and allow the production of antibodies without immunisation and without the use of animals (reviewed in Winter et al., 1994).
  • Human antibodies against large numbers of different antigens, including human proteins, can be produced by phage selection of single-chain Fv (scFv; Nissim et al., 1994) or Fab fragments (Griffiths et al., 1994).
  • scFv single-chain Fv
  • Fab fragments fragments
  • phage display was used extensively for the selection of peptides and antibodies, it had its limitations when it came to the expression of unknown sequences from cDNA libraries. As many of these sequences contain stop codons in their 3' untranslated regions, one cannot directly fuse these sequences to the N-terminus of a phage coat protein.
  • cysteines were engineered at the N- and C-termini of each of the leucine zippers, providing a covalent link of the cDNA gene products to the genetic instructions required for their production.
  • the physical link between phenotype and genotype in phage display allows selective isolation and amplification of a particular phage encoding a desired gene product from pools of millions of phage (Kay et al., 1996). Selection is accomplished by interaction between the displayed gene product and a ligand immobilized on a solid phase. The selected phage are amplified by infection of E. coli cells which, after helper rescue, produce large numbers of new phage. Successive rounds of phage selection and amplification allow selective enrichment of phage displaying gene products with affinity for a desired ligand.
  • target molecules have been immobilized on plastic surfaces, mainly immunotubes or microtiter plate wells (Harrison et a/., 1996).
  • magnetic particles have been used for phage display selection (Hawkins et al., 1992, Griffiths et al., 1994, Low et al., 1996, Schier et al., 1996a; Schier et al., 1996b, McConnell et al. 1998, McConnell et al., 1999, Kirkham et al., 1999).
  • these methods involve the manual handling of the samples and are cumbersome and time-consuming. Accordingly, these methods allow the simultaneous processing of only a very limited number of samples, i.e.
  • the technical problem underlying the present invention was to provide a method that allows the reliable, simultaneous and time-saving high-throughput selection of various members of pairs of interacting molecules.
  • the present invention relates to a method for the selection of at least one member of a number of specifically interacting molecules, said method comprising as the first step involving the contact of said interacting molecules:
  • step (b) subjecting the product obtained in step (a) to at least one washing step;
  • steps (d) providing said first and/or second molecule selected by steps (a) to (c), wherein steps (a), (b) and (c) are carried out in (a) container(s), preferably representing an arrayed form, e.g. in (a) microtiter plate(s), using an automated device comprising a magnetic particle processor (Fig. 1 ).
  • the method of the present invention shows several unexpected advantages in terms of sensitivity, control and automation: First, the number of magnetic particles can be scaled down compared to the manual techniques (e.g. 10-fold to 2 ⁇ l or 1.34 x 10 6 Dynabeads M-280 Streptavidin, Dynal). This causes much less unspecific background binding resulting in a distinct reduction of false positive results.
  • washing and incubation conditions can be reproducibly customized. Most importantly, it is envisaged in accordance with the present invention that washing speeds are adjusted to cause different stringencies of selection. This will enable the predictable selection of interacting molecules with different binding affinities.
  • the washing step which may be repeated at least once in each round of selection is designed to remove first molecules that did not specifically interact with/bind to said second molecules. Appropriate washing conditions can be taken from the appended examples or devised by the person skilled in the art without undue burden.
  • the magnetic particle processor comprised in said automated device is used to transfer the magnetic particles between wells of microtiter plates prefilled with the corresponding solutions by capturing the magnetic particles in a first well and releasing the same in a second well of a different microtiter plate, the position of said second well corresponding to the position of said first well.
  • This allows high-throughput selection of interacting molecules as large numbers of, e.g., library clones can be handled in parallel, and the selection of interacting molecules from, e.g., two libraries can be used to create interaction catalogues.
  • a “selection round” comprises steps (a) to (c). Accordingly, the phrase "first step involving the contact of said interacting molecules” denotes the contacting step of the first selection round as compared to second, third, etc. steps involving the contact of said interacting molecules of potential further selection rounds that may be performed subsequently to the first selection round (see below).
  • a preferred mode of the selection at high-throughput of the invention comprises the following steps: interacting molecules (e.g., anti-protein scFv antibodies) are selected from molecular libraries by a combination of phage display and magnetic bead technology. Proteins expressed from arrayed cDNA libraries are bound to magnetic beads via a suitable molecular tag (e.g., His 6 or Biotin). Phage displaying specifically interacting molecules are then fished from a library by binding to their interaction partners attached to the beads. This selection involves a sequence of binding and washing steps and was adapted to high throughput using a magnetic particle processor (Labsystems, Helsinki, Finland). Selected molecules are then tested for specificity also employing the magnetic particle processor.
  • interacting molecules e.g., anti-protein scFv antibodies
  • Said first and second molecule may be members of libraries, e.g., an antibody and an antigen library, respectively, i.e. two different libraries.
  • said first and second molecule may be members of the same library.
  • one molecule i.e. the first or the second molecule
  • the other molecule is a compound or a variety of compounds of predetermined specificity.
  • Other options to employ first and second molecules from still different origins or combinations of origins are within the skills of the person skilled in the art.
  • said first and/or second molecule is an organic molecule and/or a mixture of organic and/or inorganic molecules.
  • said first and/or second molecule is a hapten.
  • said first and/or second molecule is a cDNA expression product, and/or a (poly)peptide, and/or a nucleic acid, and/or a lipid, and/or a sugar, and/or a steroid, and/or a hybrid of said molecules.
  • said cDNA expression product is an antibody or a fragment or a derivative thereof, an enzyme or a fragment thereof, a surface protein or a fragment thereof, or a nucleic acid-binding protein or a fragment thereof.
  • Derivatives and fragments of antibodies are well known in the art and comprise, e.g., F(ab') 2 , Fab, Fv or single chain Fv antibody fragments (see, e.g., Harlow and Lane, "Antibodies, a laboratory manual", CHS Press, 1988, Cold Spring Harbor, N.Y.).
  • said first molecule is a (poly)peptide presented on the surface of organisms (e.g. phage, viruses, bacteria, eukaryotic cells) and/or organelles (e.g. ribosome) and/or soluble molecules (e.g. nucleic acids, protein-nucleic acid hybrids) and the method further comprises after step (b) and prior to step (c) the step of:
  • organisms e.g. phage, viruses, bacteria, eukaryotic cells
  • organelles e.g. ribosome
  • soluble molecules e.g. nucleic acids, protein-nucleic acid hybrids
  • step (b') amplifying a (poly)peptide specifically interacting with said second molecule, wherein step (b') is carried out in (a) container(s) preferably representing an arrayed form, e.g. in (a) microtiter plate(s).
  • the magnetic particle processor may be used to transfer the magnetic particles (to which said bacteriophage is bound via said (poly)peptide specifically interacting with said second molecule) to bacterial culture(s).
  • the automated device further comprises a shaking device that may be used for shaking the bacterial culture(s) during amplification of said bacteriophages.
  • said library of first molecules (library 1 ) is preabsorbed with unloaded magnetic particles and/or molecules competitive (cross-reactive) to second molecules (target, library 2).
  • this step ensures that phages unspecifically interacting with the magnetic particles are removed from the phage mixture and only bacteriophages displaying a specifically interacting molecule are selected via this specific interaction. In other words, this step may be performed to further reduce the number of false positive clones.
  • the method of the present invention further comprises after step (c) and prior to step (d) the step of:
  • step (c') repeating steps (a), (b) and (c) and, optionally, step (b') at least once.
  • steps (c) and (c') are performed in parallel.
  • steps (c) and (c') of the method of the present invention are each carried out in microtiter plates. This advantageously allows the simultaneous performance of steps (c) and (c') in different microtiter plates which further reduces the time required for practicing the method of the present invention.
  • said number of specifically interacting molecules is a pair of interacting molecules.
  • said number of specifically interacting molecules are three or more interacting molecules.
  • the method of the present invention further comprises the step of characterizing said first and/or second molecule and/or the corresponding genetic information.
  • nucleic acid sequencing e.g., nucleic acid sequencing, southern-, northern-, and colony hybridization
  • primer extension analysis e.g., primer extension analysis, RNase protection assay, gel shift analysis, western-blotting, ELISA, immunoprecipitation assay, indirect immunofluorescence analysis, and FACS
  • FACS fluorescence analysis
  • said second molecule (target) is affixed to said magnetic particle via an affinity tag (e.g. a metal-chelating tag, an epitope tag, an enzyme binding domain, calmodulin, biotin, Strep-tag, protein A, protein G or protein L) (Fig. 2).
  • an affinity tag e.g. a metal-chelating tag, an epitope tag, an enzyme binding domain, calmodulin, biotin, Strep-tag, protein A, protein G or protein L
  • one of the above-mentioned compounds advantageously ensures that said second molecule is affixed to said magnetic particle in a controlled manner and in a predictable orientation, thereby minimally affecting the three-dimensional structure of said second molecule and, consequently, the interacting capacities.
  • the use of the above-mentioned compounds allows the direct loading of magnetic particles with second molecules from protein mixtures like, e.g., crude extracts or cell lysates. This is particularly important for high-throughput selection since purification of large numbers of different second molecules is not necessary.
  • the present invention also encompasses the unspecific adsorption of second molecules, e.g., to magnetic particles coated with a plastic surface and/or the covalent binding of second molecules, e.g., via functional groups such as NH 2 -, COOH-, SH-groups.
  • functional groups such as NH 2 -, COOH-, SH-groups.
  • said metal-chelating tag is a His-tag
  • said epitope tag is an HA-tag, a c-myc-tag, a VSV-G-tag, an ⁇ -tubulin-tag, a B-tag, an E- tag, FLAG, a His-tag, an HSV-tag, a Pk-tag, a protein C-tag, a T7-tag, EpiTagTM, a V5- tag or an S-tag
  • said enzyme binding domain is cellulose binding domain, barnase or maltose binding protein.
  • step (c) is effected by immunological means.
  • step (c) is effected by ELISA, RIA, western/colony blotting, FACS or immunohistochemistry.
  • step (c) is effected in (micro-)array format, preferably on a membrane and/or filter and/or a glas slide and/or in a microtiter plate.
  • the present invention also relates to a method for the production of a pharmaceutical composition
  • a method for the production of a pharmaceutical composition comprising the steps of the method of the present invention and further the step of formulating said first and/or second molecule selected and/or characterized by the method described hereinabove or a functionally and/or structurally equivalent derivative thereof in a pharmaceutically acceptable form.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier and/or diluent.
  • suitable pharmaceutical carriers include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc.
  • Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration. The dosage regimen will be determined by the attending physician and clinical factors.
  • dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently.
  • a typical dose can be, for example, in the range of 0.001 to 1000 ⁇ g (or of nucleic acid for expression or for inhibition of expression in this range); however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors.
  • the regimen as a regular administration of the pharmaceutical composition should be in the range of 1 ⁇ g to 10 mg units per day. If the regimen is a continuous infusion, it should also be in the range of 1 ⁇ g to 10 mg units per kilogram of body weight per minute, respectively.
  • compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents examples include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
  • Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
  • the pharmaceutical composition of the invention may comprise further agents such as interleukins or interferons depending on the intended use of the pharmaceutical composition.
  • the term "functionally and/or structurally equivalent derivative” as used in accordance with the present invention denotes molecules modified, e.g., by deletion, addition and/or substitution of certain parts thereof but essentially maintaining their capacity of specifically interacting with said first or second molecule selected by the method of the present invention. Also encompassed by this term are molecules that have been modified in order," e.g., to increase their half-lifes in a subject to which they have been administered, to increase the rate of their uptake, to increase their affinity to their interacting counterparts or to increase the excretion rate of the corresponding metabolized end products.
  • nucleic acids such molecules may be peptide nucleic acids or nucleic acids comprising, e.g., methylphosphonate- or phosphorothioate-bonds instead of phosphodiester-bonds.
  • Methods for the synthesis of derivatives that, e.g., show the same three-dimensional structure than the originally identified molecule are known in the art and include, e.g., peptidomimetics (see, e.g., Hruby, V.J. et al., Biopolymers 43(3) (1997), 219-66; Bohm, H. J., J. Comput. Aided Mol. Des. 10(4) (1996), 265-272; Wiley, R.A. & Rich, D.
  • compositions comprising at least one of the selected interacting molecules or of derivatives as defined above, optionally in combination with a pharmaceutically acceptable carrier and/or diluent.
  • Figure 1 High-throughput selection of binding partners. Magnetic particles are transferred between wells of microtitre plates, incubated and washed using an automated magnetic particle processor. Molecules of the arrayed Library 2 (targets) are tag-bound to magnetic particles which are washed, blocked and incubated with Library 1 being, e.g., a phage display library. After washing away background phage and incubation with bacteria and helper phage, an enriched and amplified Library 1 enters the next round of selection against the same Library 2 molecules for further enrichment.
  • Targets Molecules of the arrayed Library 2 (targets) are tag-bound to magnetic particles which are washed, blocked and incubated with Library 1 being, e.g., a phage display library. After washing away background phage and incubation with bacteria and helper phage, an enriched and amplified Library 1 enters the next round of selection against the same Library 2 molecules for further enrichment.
  • Library 1 being, e.g.
  • Figure 2 Example for the selection of interacting molecules. Selection from phage display libraries of, e.g. human scFv antibody fragments recognising targets (e.g. specific expression products of a human cDNA library) tag- bound to magnetic particles.
  • targets e.g. specific expression products of a human cDNA library
  • FIG. 3 Automated magnetic particle processor (Labsystems, Helsinki, Finland) in action. Left: rod-shaped magnets and plastic caps separated, magnetic particles in solution in microtitre wells; top right: magnets in plastic caps, collection of magnetic particles to plastic caps; bottom right: transfer of magnetic particles to new pre-filled microtitre wells.
  • Figure 4 Saturation ELISA for assessment of optimal concentrations of protein targets (e.g. bGAPDH) for loading of magnetic particles.
  • protein targets e.g. bGAPDH
  • Figure 5 Polyclonal mixtures of phage representing the unselected (rounds) library 1 and the results of every round of selection screened for binding partners to the protein target used for this selection (e.g. UBI8) using magnetic particle ELISA; PTM negative control.
  • FIG. 6 Monoclonal phage (e.g. anti-UBI8) rescreened by magnetic particle phage ELISA for binding to the same protein target (e.g. UBI8); PTM negative control.
  • Example 1 Automated magnetic particle-handling An automated device (Fig. 3, Labsystems) was used for washing and incubation of magnetic particles.
  • 96-well microtitre plates e.g. CliniPlate 200, Labsystems
  • solutions 200 ⁇ l
  • magnetic particles were transferred between wells by capture to and release from rod-shaped magnets covered with plastic caps.
  • Ni-NTA Silica Beads Qiagen, Hilden, Germany
  • Dynabeads M-280 Streptavidin were used for binding of His 6 - or biotin-tagged proteins, respectively.
  • Protein targets were expressed in E. coli (strain SCSI ) liquid cultures.
  • 200 ml 2xTY medium (16 g/l Bacto-tryptone, 10 g/l yeast extract, 5 g/l NaCI, pH 7.0) containing 100 ⁇ g/ml ampicillin were inoculated with 2 ml of an overnight culture and shaken at 37°C until an OD 600 of 0.8 was reached.
  • Isopropyl-b-D-thiogalactopyranosid (IPTG) was added to a final concentration of 1 mM. The culture was shaken for 4-6 h at 30 or 37°C.
  • Cells were harvested by centrifugation at 2,100 g for 10 min, resuspended in 5 ml Lysis Buffer (50 mM NaH 2 PO 4 , 0.3 M NaCI, 10 mM Imidazole, 0.1 mM PMSF, pH 8.0) containing 0.25 mg/ml lysozyme, 10 ⁇ g/ml DNase and 10 ⁇ g/ml RNase and incubated on ice for 30 min. DNA was sheared with an ultrasonic homogeniser (Sonifier 250, Branson Ultrasonics, Danbury, USA) for 3 x 1 min at 50% power on ice. The lysate was cleared by centrifugation at 10,000 g for 30 min.
  • Lysis Buffer 50 mM NaH 2 PO 4 , 0.3 M NaCI, 10 mM Imidazole, 0.1 mM PMSF, pH 8.0
  • DNA was sheared with an ultrasonic homogeniser (Sonifier 250, Branson Ultrasonics,
  • Ni-NTA agarose (Qiagen) was added and mixed by shaking at 4°C for 1 h. The mixture was poured into a column which was subsequently washed with ten bed volumes of Lysis Buffer containing 20 mM imidazole. Protein was eluted in Lysis Buffer containing 250 mM imidazole and was dialysed against Phosphate-Buffered Saline (PBS, 10 mM Phosphate buffer, 2.7 mM KCI, 137 mM NaCI, pH 7.4) at 4°C overnight.
  • PBS Phosphate-Buffered Saline
  • Proteins were either expressed as fusion proteins with a His 6 - and/or biotin-tag attached (Lueking et al., 1999) or were biotinylated in vitro using ImmunoPure NHS-SS-Biotin (Pierce, Rockford USA) and the efficiency of biotinylation was determined by ImmunoPure HABA (Pierce).
  • IPTG was added to a final concentration of 1 mM.
  • Cells were grown for 4-6 h at 30 or 37°C, harvested by centrifugation at 6,000 g for 10 min, washed by resuspension in Lysis Buffer (50 mM NaH 2 PO 4 , 0.3 M NaCI, 10 mM Imidazole, 0.1 mM PMSF, pH 8.0) containing 0.25 mg/ml lysozyme, 10 ⁇ g/ml DNase and 10 ⁇ g/ml RNase and incubated on ice for 1 h.
  • Lysis Buffer 50 mM NaH 2 PO 4 , 0.3 M NaCI, 10 mM Imidazole, 0.1 mM PMSF, pH 8.0
  • coli SCSI cells from 384- well library plates (Genetix, Wales, U.K.) that had been stored at -80°C.
  • replicating devices carrying 96 steel pins were used. After overnight growth at 37°C with vigorous shaking, 900 ⁇ l of prewarmed medium were added to the cultures, and incubation was continued for 1 h.
  • IPTG was added to a final concentration of 1 mM. All following steps, including centrifugations, were also done in 96-well format.
  • Cells were harvested by centrifugation at 1 ,900 g (3,400 rpm) for 10 min, washed by resuspension in Phosphate Buffer, centrifuged for 5 min and lysed by resuspension in 150 ⁇ l Buffer A (6 M Guanidinium-HCI, 0.1 M NaH 2 PO 4 , 0.01 M Tris-HCI, pH 8.0). Bacterial debris was pelleted by centrifugation at 4,000 rpm for 15 min.
  • Magnetic particles (10 ⁇ l or 250 ⁇ g Ni-NTA Silica Beads, Qiagen, or 20 ⁇ l or 1.34 x 10 7 particles, Dynabeads M-280 Streptavidin, Dynal) were washed twice in PBST (PBS, 0.1 % Tween 20) and loaded with ligands as follows.
  • Magnetic particles were incubated for 1 h at RT in 200 ⁇ l total cell lysate.
  • Examples were proteins like expression products of a human cDNA library as described (Lueking et al., 1999).
  • proteins like human glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Swiss-Prot P04406), a C-terminal fragment (40.3 kd) of human heat shock protein 90 alpha (HSP90a, Swiss-Prot P07900), rat immunoglobulin heavy chain binding protein (BIP, Swiss-Prot P06761 ), tubulin alpha-1 chain (TUBal , Swiss-Prot P04687), calcium-binding protein ERC-55 precursor (ERC55, Swiss-Prot Q14257), transcription elongation factor S-ll (HS-II-T1 , Swiss-Prot Q15560), transcription factor ETR101 (ETR101 , Swiss-Prot Q03827), peptidyl-prolyl cis-trans isomerase A (EC5218, Swiss-Prot P05092) and Ubiquitin (UBIQ- HUMAN, SWISS-Prot P02248).
  • GPDH human glyceraldeh
  • Magnetic particles (10 ⁇ l or 250 ⁇ g Ni-NTA Silica Beads, Qiagen, or 2 ⁇ l or 1.34 x 10 6 particles, Dynabeads M-280 Streptavidin, Dynal) were incubated with primary and secondary antibodies diluted in PTM for 30 min at RT each and washed twice in PBST after antibody incubations.
  • HRP horseraddish peroxidase
  • Example 7 Saturation ELISA Target dilutions (100 nM - 25 ⁇ M) were prepared in 200 ⁇ l PBS containing 1 % BSA and incubated consecutively with two aiiquots of magnetic particles (10 ⁇ l or 250 ⁇ g Ni-NTA Silica Beads, Qiagen, or 20 ⁇ l or 1.34 x 10 7 particles, Dynabeads M-280 Streptavidin, Dynal) for 1 h at RT each. Magnetic particles were washed twice in PBST, blocked with PTM for 1 h at RT, incubated with primary and secondary antibodies diluted in PTM for 30 min at RT each and washed twice in PBST after antibody incubations. Secondary antibodies labelled with HRP were detected using ABTS solution and measured as OD 405 nm.
  • Phage suspensions (10 12 phage of unselected libraries or the Multiscreen flow- through after phage amplification between selection rounds) were equilibrated and preabsorbed by incubation with unloaded magnetic particles (10 ⁇ l or 250 ⁇ g Ni-NTA Silica Beads, Qiagen, or 25 ⁇ l or 1.68 x 10 7 particles, Dynabeads M-280 Streptavidin, Dynal) in 200 ⁇ l PTM for 1 h at RT.
  • unloaded magnetic particles (10 ⁇ l or 250 ⁇ g Ni-NTA Silica Beads, Qiagen, or 25 ⁇ l or 1.68 x 10 7 particles, Dynabeads M-280 Streptavidin, Dynal
  • Magnetic particles (10 ⁇ l or 250 ⁇ g Ni-NTA Silica Beads, Qiagen, or 20 ⁇ l or 1.34 x 10 7 particles, Dynabeads M-280 Streptavidin, Dynal) were loaded with targets and blocked as described above, incubated with preabsorbed phage for 1 h at RT and washed in PBST several times according to the number of the selection round. E. coli TG1 cells were incubated with the washed magnetic particles for 30 min at RT.
  • TG1 cells were resuspended in 200 ⁇ l 2xTY containing 100 ⁇ g/ml ampicillin and 60 ⁇ g/ml kanamycin, transferred to a microtitre plate (e.g. CliniPlate 200, LabSystems) and vigorously shaken overnight at 30°C. Cultures were transferred to a Durapore 0.65 ⁇ plate (Millipore) and sucked through on a Multiscreen vacuum device (Millipore). The flow-through was collected in a microtitre plate (e.g. CliniPlate 200, LabSystems) and was used as starting material (phage suspension) for the next round of selection.
  • a microtitre plate e.g. CliniPlate 200, LabSystems
  • Phage were prepared from overnight cultures as described above. Magnetic particles (10 ⁇ l or 250 ⁇ g Ni-NTA Silica Beads, Qiagen, or 2 ⁇ l or 1.34 x 10 6 particles, Dynabeads M-280 Streptavidin, Dynal) were loaded with targets and blocked as described above, incubated with phage suspensions (10 10 -10 11 phage) for 30 min at RT and washed twice in PBST. For detection, magnetic particles were incubated with anti-M13 HRP (1 :5,000) in PTM for 30 min at RT, washed twice in PBST and incubated in ABTS solution which was measured at OD 405 nm.
  • Example 11 PCR and DNA sequencing
  • Example 13 Specific tag-binding of targets to magnetic particles
  • Tag-binding is specific for the labelled molecules and ensures their proper orientation on the magnetic particles, in contrast, unspecific adsorption of proteins to plastic surfaces leads to partial denaturation and destruction of epitopes. Tag-binding also enables direct loading of magnetic particles with targets from protein mixtures like crude extracts or cell lysates. This is particularly important for high- throughput selection technology, avoiding purification of large numbers of different proteins or other targets.
  • concentration of target molecules on solid surfaces is a critical parameter for the selection of binding partner molecules.
  • Optimal concentrations of protein targets e.g. bGAPDH
  • concentrations of 5-10 ⁇ M purified target e.g. 200-400 ⁇ g/ml bGAPDH
  • concentrations of 5-10 ⁇ M purified target were found to cause saturation of 10 ⁇ l (250 ⁇ g) Ni-NTA Silica Beads (Qiagen) or 20 ⁇ l (1.34 x 10 7 particles) Dynabeads M-280 Streptavidin (Dynal).
  • concentrations are in excess of saturating concentrations of other plastic surfaces (e.g.
  • microtitre plates Kala et al., 1997) and confirm the high binding capacity of magnetic particles, reflecting their increased surface area. While it is advisable to work with saturating concentrations if possible, some protein targets can not be produced in sufficient amounts. In such cases, sub-saturating concentrations of protein targets were used successfully, due to the high sensitivity of the magnetic particle ELISA (data not shown).
  • Phage display libraries e.g. human scFv antibody fragment libraries, Tomlinson, unpublished
  • Phage titres were recorded after each round of selection to monitor the efficiency of phage amplification (data not shown).
  • polyclonal mixtures of phage representing the unselected library and the results of every round of selection were screened for binding partners to the protein target used for this selection (e.g. UBI8, Fig. 5). Positive mixtures were cloned, and single colonies were rescreened by magnetic particle phage ELISA for binding to the same protein target (e.g. UBI8, Fig. 6).
  • Magnetic bead enzyme-linked immunosorbent assay detects antigen-specific binding by phage-displayed scFv antibodies that are not detected with conventional ELISA.
  • Filamentous fusion phage novel expression vectors that display cloned antigens on the virion surface. Science. 228, 1315-1317.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La présente invention concerne un procédé de sélection d'au moins un élément parmi un nombre de molécules interagissant de manière spécifique, ledit procédé étant effectué dans (a) un ou plusieurs contenants ayant de préférence la forme d'un réseau, tel que par exemple (a) une ou plusieurs plaques à microtitration, au moyen d'un dispositif automatisé comprenant un processeur de particules magnétiques. Dans une autre forme de réalisation, la présente invention concerne un procédé de production d'une composition pharmaceutique dans lequel on utilise le procédé de la présente invention et une étape de formulation d'au moins une desdites molécules interagissant de manière spécifique sélectionnée et/ou caractérisée par le procédé précité ou d'un dérivé fonctionnellement et/ou structurellement équivalent de cette dernière sous une forme pharmaceutiquement acceptable.
PCT/EP2000/006271 1999-07-05 2000-07-04 Procede de selection a haut rendement de molecules en interaction WO2001002554A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00949254A EP1198566A2 (fr) 1999-07-05 2000-07-04 Procede de selection a haut rendement de molecules en interaction
CA002378573A CA2378573A1 (fr) 1999-07-05 2000-07-04 Procede de selection a haut rendement de partenaires de liaison

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99112970 1999-07-05
EP99112970.1 1999-07-05

Publications (2)

Publication Number Publication Date
WO2001002554A2 true WO2001002554A2 (fr) 2001-01-11
WO2001002554A3 WO2001002554A3 (fr) 2001-04-19

Family

ID=8238519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006271 WO2001002554A2 (fr) 1999-07-05 2000-07-04 Procede de selection a haut rendement de molecules en interaction

Country Status (3)

Country Link
EP (1) EP1198566A2 (fr)
CA (1) CA2378573A1 (fr)
WO (1) WO2001002554A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003046198A2 (fr) * 2001-11-28 2003-06-05 Graffinity Pharmaceuticals Ag Procede de selection et d'identification de molecules peptidiques ou proteiques par presentation a la surface de phages
WO2003102591A2 (fr) * 2001-11-28 2003-12-11 Graffinity Pharmaceuticals Ag Procede d'identification de partenaires d'interaction au moyen de l'expression phagique
EP2568289A3 (fr) * 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
US8557743B2 (en) 2002-09-05 2013-10-15 Dyax Corp. Display library process
US9267952B2 (en) 2008-11-05 2016-02-23 Morphosys Ag Deconvolution method
WO2020157381A1 (fr) 2019-01-29 2020-08-06 Teknologian Tutkimuskeskus Vtt Oy Procédés de criblage de polypeptides capables de se lier à des molécules cibles spécifiques et outils associés

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057311A2 (fr) * 1998-04-30 1999-11-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveau procede permettant l'identification de clones conferant une propriete biologique desiree dans une banque d'expression
DE19854003A1 (de) * 1998-11-18 2000-05-25 Jenoptik Jena Gmbh Simultanes Magnetpartikelhandling in zweidimensionaler Anordnung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212164D0 (en) * 1992-06-09 1992-07-22 Medical Res Council Preparation of nucleic acids
EP1130397B1 (fr) * 1993-02-01 2006-10-11 Thermo Electron Oy Equipment pour la détermination d'un analyte dans un échantillon
DE29614623U1 (de) * 1996-08-23 1996-12-19 AGOWA Gesellschaft für molekularbiologische Technologie mbH, 12489 Berlin Magnetseparator zum Trennen und Waschen von paramagnetischen Partikeln sowie zur Elution von Stoffen, welche an die paramagnetischen Partikel gebunden wurden

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057311A2 (fr) * 1998-04-30 1999-11-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveau procede permettant l'identification de clones conferant une propriete biologique desiree dans une banque d'expression
DE19854003A1 (de) * 1998-11-18 2000-05-25 Jenoptik Jena Gmbh Simultanes Magnetpartikelhandling in zweidimensionaler Anordnung

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B]SSOW ET AL: "A METHOD FOR GLOBAL PROTEIN EXPRESSION AND ANTIBODY SCREENING ON HIGH-DENSITY FILTERS OF AN ARRAYED cDNA LIBRARY" NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 26, no. 21, November 1998 (1998-11), pages 5007-5008, XP002114084 ISSN: 0305-1048 cited in the application *
CHOI J -W ET AL: "A new magnetic bead-based, filterless bio-separator with planar electromagnet surfaces for integrated bio-detection systems" SENSORS AND ACTUATORS B,ELSEVIER SEQUOIA S.A., LAUSANNE,CH, vol. 68, no. 1-3, 25 August 2000 (2000-08-25), pages 34-39, XP004216589 ISSN: 0925-4005 *
KALA MRINALINI ET AL: "Magnetic bead enzyme-linked immunosorbent assay (ELISA) detects antigen-specific binding by phage-displayed scFv antibodies that are not detected with conventional ELISA." ANALYTICAL BIOCHEMISTRY, vol. 254, no. 2, 15 December 1997 (1997-12-15), pages 263-266, XP002154707 ISSN: 0003-2697 cited in the application *
LEHRACH H ET AL: "ROBOTICS, COMPUTING, AND BIOLOGY. AN INTERDISCIPLINARY APPROACH TO THE ANALYSIS OF COMPLEX GENOMES" INTERDISCIPLINARY SCIENCE REVIEWS,GB,HEYDEN, LONDON, vol. 22, no. 1, 1997, pages 37-44, XP000863340 ISSN: 0308-0188 *
LUEKING A ET AL: "Protein microarrays for gene expression and antibody screening" ANALYTICAL BIOCHEMISTRY,ACADEMIC PRESS, SAN DIEGO, CA,US, vol. 270, 1999, pages 103-111, XP002127382 ISSN: 0003-2697 cited in the application *
MAIER ET AL: "AUTOMATED ARRAY TECHNOLOGIES FOR GENE EXPRESSION PROFILING" DRUG DISCOVERY TODAY,GB,ELSEVIER SCIENCE LTD, vol. 2, no. 8, August 1997 (1997-08), pages 315-324, XP002103832 ISSN: 1359-6446 *
MCCONNELL STEPHEN J ET AL: "Biopanning phage display libraries using magnetic beads vs. polystyrene plates." BIOTECHNIQUES, vol. 26, no. 2, February 1999 (1999-02), pages 208-214, XP002154708 ISSN: 0736-6205 cited in the application *
See also references of EP1198566A2 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003046198A2 (fr) * 2001-11-28 2003-06-05 Graffinity Pharmaceuticals Ag Procede de selection et d'identification de molecules peptidiques ou proteiques par presentation a la surface de phages
WO2003102591A2 (fr) * 2001-11-28 2003-12-11 Graffinity Pharmaceuticals Ag Procede d'identification de partenaires d'interaction au moyen de l'expression phagique
WO2003102591A3 (fr) * 2001-11-28 2004-03-18 Graffinity Pharmaceuticals Ag Procede d'identification de partenaires d'interaction au moyen de l'expression phagique
WO2003046198A3 (fr) * 2001-11-28 2004-03-25 Graffinity Pharmaceuticals Ag Procede de selection et d'identification de molecules peptidiques ou proteiques par presentation a la surface de phages
US8557743B2 (en) 2002-09-05 2013-10-15 Dyax Corp. Display library process
US9670481B2 (en) 2002-09-05 2017-06-06 Dyax Corp. Display library process
US10577598B2 (en) 2002-09-05 2020-03-03 Dyax Corp. Display library process
US11479877B2 (en) 2002-09-05 2022-10-25 Takeda Pharmaceutical Company Limited Display library process
US9267952B2 (en) 2008-11-05 2016-02-23 Morphosys Ag Deconvolution method
EP2568289A3 (fr) * 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
WO2020157381A1 (fr) 2019-01-29 2020-08-06 Teknologian Tutkimuskeskus Vtt Oy Procédés de criblage de polypeptides capables de se lier à des molécules cibles spécifiques et outils associés
US20220214336A1 (en) * 2019-01-29 2022-07-07 Teknologian Tutkimuskeskus Vtt Oy Methods for screening polypeptides capable of binding specific target molecules and tools related thereto

Also Published As

Publication number Publication date
WO2001002554A3 (fr) 2001-04-19
EP1198566A2 (fr) 2002-04-24
CA2378573A1 (fr) 2001-01-11

Similar Documents

Publication Publication Date Title
Aghebati-Maleki et al. Phage display as a promising approach for vaccine development
Breitling et al. A surface expression vector for antibody screening
JP3210342B2 (ja) 全合成親和性試薬
US8735330B2 (en) pVII phage display
JP4564062B2 (ja) 抗体ライブラリーをスクリーニングする方法
JP2002514919A (ja) 多価ライブラリーおよびポリクローナルライブラリー
AU5986400A (en) Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US8969253B2 (en) Method for screening phage display libraries against each other
CN108017712B (zh) 一种鲨鱼抗体来源的蛋白骨架及其应用
KR100961392B1 (ko) 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터
US20160312383A1 (en) Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands
JP3901222B2 (ja) 細胞への抗体結合の検出のための組成物および方法
Böttger et al. Epitope mapping using phage display peptide libraries
US10191049B2 (en) Screening methods and uses thereof
US6686154B2 (en) Screening of phage displayed peptides without clearing of the cell culture
Hust et al. Selection of recombinant antibodies from antibody gene libraries
EP1198566A2 (fr) Procede de selection a haut rendement de molecules en interaction
JP2002503085A (ja) タンパク質の製造のための磁気活性化細胞の分類
Yan et al. Generation and characterization of a novel single-chain antibody fragment specific against human fibrin clots from phage display antibody library
Crameri et al. Direct selection of cDNAs by phage display
IL181928A (en) Methods for screening a library of molecules
McGregor et al. External surface display of proteins linked to DNA-binding domains
Dhial et al. Selection of phage display peptides against Pasteurella multocida using suspension method of biopanning
Palombo 10 Phage selection for biopanning
Chen et al. Isolation of human antibodies against hepatitis E virus from phage display library by immobilized metal affinity chromatography

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2378573

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000949254

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10031131

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000949254

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWR Wipo information: refused in national office

Ref document number: 2000949254

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000949254

Country of ref document: EP